Expertise in
65
conditions

Dr. Ying Zhuo

Hematology | Hematology Oncology
7360 West Deschutes Avenue, 
Kennewick, WA 
Accepting New Patients
Offers Telehealth
Expertise in
65
conditions
7360 West Deschutes Avenue, 
Kennewick, WA 

Overview

Ying Zhuo is a Hematologist and a Hematologist Oncology provider in Kennewick, Washington. Dr. Zhuo is highly rated in 65 conditions, according to our data. Her top areas of expertise are Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, WT1-Related Wilms Tumor Syndromes, and Paget Disease of the Breast. Dr. Zhuo is currently accepting new patients.

Her clinical research consists of co-authoring 94 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Hematology Oncology

Licenses

Internal Medicine in WA

Hospital Affiliations

Good Shepherd Medical Center
Prosser Memorial Hospital
Kadlec Regional Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Prominence Health
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

7360 West Deschutes Avenue, Kennewick, WA 99336

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: January 09, 2026
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

94 Total Publications

Analysis of clinicopathological and genetic characteristics of three cases of Li-Fraumeni syndrome
Analysis of clinicopathological and genetic characteristics of three cases of Li-Fraumeni syndrome
Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology
Published: December 08, 2025
Similar Doctors
Expertise in
62
conditions
Dr. Basir U. Haque
Hematology Oncology | Hematology
Expertise in
62
conditions
Dr. Basir U. Haque
Hematology Oncology | Hematology
7360 West Deschutes Avenue, 
Kennewick, WA 
 (2.2 miles away)
509-942-2540
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Basir Haque is a Hematologist Oncology specialist and a Hematologist in Kennewick, Washington. Dr. Haque is highly rated in 62 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Lynch Syndrome, Colorectal Cancer, and Thrombocytopenia. Dr. Haque is currently accepting new patients.

Expertise in
72
conditions
Dr. Eric O. Gamboa
Hematology Oncology | Hematology
Expertise in
72
conditions
Dr. Eric O. Gamboa
Hematology Oncology | Hematology
7360 West Deschutes Avenue, 
Kennewick, WA 
 (2.2 miles away)
509-942-2540
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Gamboa is a Hematologist Oncology specialist and a Hematologist in Kennewick, Washington. Dr. Gamboa is highly rated in 72 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), and Colorectal Cancer. Dr. Gamboa is currently accepting new patients.

Expertise in
76
conditions
Dr. Rangaswamy A. Chintapatla
Hematology Oncology | Oncology
Expertise in
76
conditions
Dr. Rangaswamy A. Chintapatla
Hematology Oncology | Oncology
7360 West Deschutes Avenue, 
Kennewick, WA 
 (2.2 miles away)
509-942-2540
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rangaswamy Chintapatla is a Hematologist Oncology specialist and an Oncologist in Kennewick, Washington. Dr. Chintapatla is highly rated in 76 conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Myelodysplastic Syndrome (MDS), and Familial Colorectal Cancer. Dr. Chintapatla is currently accepting new patients.

Frequently Asked Questions about Dr. Ying Zhuo

How do I make an appointment with Dr. Ying Zhuo?

You can book an appointment with Dr. Ying Zhuo by calling their office at 509-942-2540. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ying Zhuo a top-rated expert for Chromophobe Renal Cell Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ying Zhuo is classified as an Distinguished expert for Chromophobe Renal Cell Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ying Zhuo specialize in?

While Dr. Ying Zhuo is a Hematology, they have specific expertise in Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, and WT1-Related Wilms Tumor Syndromes. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ying Zhuo participate in research or clinical trials?

Yes. Dr. Ying Zhuo has published 94 articles and abstracts on conditions like Chromophobe Renal Cell Carcinoma. You can view a list of Dr. Ying Zhuo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ying Zhuo accept my insurance?

Dr. Ying Zhuo accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 509-942-2540 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zhuo's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 48 Advanced Conditions
    View All 132 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile